sitagliptin Articles
Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds
26 February 2013
Merck warned for not carrying out post-approval sitagliptin study
28 February 2012
Diabetes Rxing in China and S Korea
7 December 2011
Merck & Co drops combo diabetes drug Janacti filing in Europe; presents data on discontinued vorapaxar study
15 November 2011
Merck & Co debuts Nexplanon in USA; gets negative FDA response on Zoely and Saflutan
10 November 2011
Most surveyed physicians in Europe expect to increase Rxing of GLP-1 analogues and DPP-IV inhibitors
18 August 2011
Type 2 diabetes agents - DPP-IV inhibitors - will be main beneficiaries of pioglitazone problems
1 August 2011
Lupin in deal with Abbott and Fournier for Antara; Sun Pharma to sell Merck & Co diabetes drugs
27 April 2011
Merck & Co/Banyu: Correction
19 October 2010
Merck & Co’s Banyu unit warned about paying Japanese doctors for attending conferences
11 October 2010
Impact of Avandia restrictions could benefit Januvia, Byetta and Victoza, US physician survey reveals
7 October 2010
New data on Boehringer Ingelheim’s linagliptin, Novo Nordisk’s degludec and Merck & Co’s Januvia presented at EASD
23 September 2010
Type 2 diabetes drug market to nearly double to $36 billion in 2019, boosted by news drugs; research shows many patients not taking their insulin
23 September 2010
Novo Nordisk reports new data demonstrating superior efficacy of Victoza over Januvia in type 2 diabetes
23 April 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
Merck & Co signs performance-based contract with CIGNA
24 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Merck & Co 1st-qtr profit slumps 57%
21 April 2009
Amylin narrows 1st-qtr loss 34% to $47M
20 April 2009
FDA panel backs safety of B-MS/AZ' Onglyza
2 April 2009
Stock Commentary - New York week to Mar 16, 2009
23 March 2009
Report says Novo and US Merck will top 2014 metabolism market
12 January 2009
Merck & Co's 2009 outlook below predictions due to forex effects and restructuring costs
15 December 2008
Januvia reduces blood sugar in elderly diabetics
1 December 2008
Labor unions attack Januvia marketing
1 December 2008
EMEA's PDCO thumbs-up to eight PIPs
3 November 2008
Byetta: better post-meal glucose reduction than Januvia
15 September 2008
Two-year efficacy for Januvia plus metformin
15 September 2008
India govt "considering" bulk drug deals
28 July 2008
Januvia lowers hypoglycemia risk vs glipizide
16 June 2008
Vioxx costs see Merck & Co swing to $1.6B loss
4 February 2008
Japan stock market week to Nov 14
7 January 2008
Merck & Co's 3rd-qtr 2007 sales jump 12%
29 October 2007
sNDA for Merck & Co's Januvia OKed
22 October 2007
SMC approves Januvia for type 2 diabetes
22 October 2007
Prix Galien for Abbott's Humira
8 October 2007
Prix Galien for Merck & Co's Gardasil and Januvia
27 September 2007
Merck & Co's 2nd-qtr 2007 EPS jumps 12%
30 July 2007
Japan stock market week to July 9, 2007
26 July 2007
CORRECTION: Merck & Co's Januvia
7 May 2007
Merck & Co launches Januvia in UK
30 April 2007
Stock Commentary - New York week to April 2
9 April 2007
Merck & Co's Januvia gets EC OK
2 April 2007
Merck KGaA licenses Glenmark's DPP-4 drug
12 March 2007
Stock Commentary - New York week to March 5, 2007
12 March 2007
Stock Commentary - New York week to Feb 26, 2007
5 March 2007
FDA accepts two more Januvia sNDAs
26 February 2007
Merck & Co's 4th-qtr income plunges 58%
5 February 2007
Januvia gets thumbs up from CHMP
5 February 2007
Stock Commentary - New York week to Aug 15
29 January 2007
Strong data on Merck & Co's Janumet
18 December 2006
Novartis' Galvus improves glucose control in elderly
18 December 2006
Japan stock market week to Dec 11, 2006
18 December 2006
Merck & Co's reaffirms cautious 2006 EPS
18 December 2006
Merck & Co announces trade name for MK-0431A
11 December 2006
Takeda's six-month profit drops 12.2%
13 November 2006
FDA approves Merck & Co's Januvia
23 October 2006
Merck & Co delays 2007 filing of MK-524B on formulation issue, pre-2009 launch unlikely
9 October 2006
Merck & Co 's Januvia wins approval in Mexico
14 August 2006
Banyu/Ono start Ph III trial of sitagliptin
14 August 2006
Merck & Co's MK-0431A NDA accepted by FDA
7 August 2006
Japan stock market week to June 19, 2006
26 June 2006
Novartis' Galvus overcomes poor glycemic control
19 June 2006
Merck & Co's Januiva: 'non-inferior to metformin'
13 June 2006
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
